Kornimate/medical-research-clean huggingface dataset:
speech characteristics in coronary heart disease

Conditions: Cardiovascular Diseases; Heart Diseases; Coronary Disease

Summary: to improve the predictive validity of structured interview assessments of type a behavior by comparing interviewer techniques in the multiple risk factor intervention trial (mrfit) and the western collaborative group study (wcgs). to assess whether there were interviewer differences in the predictiveness of type a behavior and its components for coronary heart disease incidence in mrfit and wcgs and if so, to assess whether the interviewer differences in disease predictiveness were related to interviewer stylistics.

background: individuals with type a behavior are characterized as hard driving, competitive, and time urgent; when asked questions they are quick to answer with emphatic speech; they perceive themselves to be striving and competing and are prone to hostility. this core of behaviors is presumed to be on a continuum of intensity with well-developed type a's at the upper end and well-developed type b's at the lower end. epidemiological studies have shown type a's to have a higher prevalence and incidence of various forms of coronary heart disease than type b's. the structured interview is a method of measuring type a behavior in which a series of questions are administered about the individual's characteristic responses to situations relevant to the type a behavior pattern, such as reaction to delay and reported frequency of anger. the interview is delivered in challenging style designed to elicit type a characteristics. in 1960, the wcgs recruited 3,154 employed men, ages 39 to 59, who were initially free of coronary heart disease and followed them for 8.5 years for coronary heart disease incidence. in 1972 mrfit began recruiting 12,866 men, ages 35 to 57, selected for elevation of one or more risk factors, but free from coronary heart disease and followed them for an average of seven years after randomization to a risk factor modification group or to a control group referred to their own physicians for treatment. both studies used the structured interview to assess type a behavior. in 1981, type a behavior was officially regarded as an independent risk factor for coronary heart disease, based largely on the findings of the wcgs. however, the mrfit did not find type a behavior to be related to coronary heart disease incidence. the manner of conducting the structured interview may have affected the predictive reliability of the type a assessments. design narrative: interviewer speech characteristics from the wcgs and mrfit structured interview tape recordings were audited and analyzed. each speech characteristic was scored with high reliability. multiple logistic regression analyses were used to control for standard risk factors. the study completion date listed in this record was obtained from the "end date" entered in the protocol registration and results system (prs) record.

Eligibility criteria:
no eligibility criteria
comprehensive study on the quality of life in cervical cancer patients

Conditions: Quality of Life; Cervical Cancer; Urodynamics; Rectum Dynamics; Sex Dysfunction; Pelvic Floor Disorders; Ovarian Reserve Function; Survivorship; Disease-free Survival; Overall Survival

Summary: this is prospective cohort study. all the patients with primary cervical cancer in the future three years in peking union medical college hospital will be included in this study. before and after the major therapy (including at least radical hysterectomy and/or radiotherapy), the patients accept (1) the questionnaires survey about quality of life; (2) urodynamic testing; (3) rectum dynamics testing and (4) ovarian reserve function. the survival outcomes (disease-free survival and overall survival) will be supplemented as secondary objectives.


Eligibility criteria:
inclusion criteria: * primary uterine cervical carcinomas * aged 18 or older * accepting major therapy (including at least radical hysterectomy and/or radiotherapy) in the study center * informed consents delivered exclusion criteria: * not meeting any of the inclusion criteria * not accepting any of the four kinds of evaluations for quality of life * recurrent patients * not achieving response after above major therapy
dehydroepiandrosterone (dhea) treatment and premature ovarian failure (pof)

Conditions: Premature Ovarian Failure

Summary: the experimental focus of this project is on the interaction of dhea treatment on pregnancy in women with open tubes, fertile male partners and evidence of premature ovarian failure.

recruitment: * new patients presenting for donor egg cycles * possible print, magazine or radio advertisement experimental plan: 1. informed consent 2. baseline studies * antral follicle counts * serum fsh, lh, e2, prog, dhea, dheas, testosterone, amh, fragile x 3. randomization * group a: dhea (25 mg three times per day) * group b: placebo 4. monitoring during treatment * all participants will have: * usg for follicle measurement * repeat serum, fsh, e2, dhea, dheas, testosterone, amh monthly during treatment. * physical examination * completion of study questionnaire regarding possible androgen effects of treatment 5. analysis plan: * primary outcome * pregnancy * pregnancy rates will be compared using logistic regression with age and pre-treatment amh as covariates. * secondary outcomes * endocrine factors * androgen side effects * primary analysis. we will perform a factorial anova for the two pretreatment factors dhea and placebo. baseline amh and age as main covariates * secondary analysis. * examine rate of change of estradiol and other endocrine response over the four cycles of treatment * compare antral follicle counts across cycles between groups * compare possible androgen related effects * power considerations: * power assumptions: alpha 0.05; 80% power spontaneous pregnancy rate for pof is less than 1% per 3 months intervention will improve pregnancy rate to 10% per 3 months. patients will be treated for 3 cycles. require 100 patients to complete treatment in each group. allow for 20% dropout will need 120 patients randomized to each group * randomization: randomization will be by permuted blocks in order to maintain an even distribution among the groups (because of the small numbers of participants) * human subjects issues * potential risks associated with dhea use * potential risk of delay of treatment for 3 months and possible natural continued loss of fertility * informed consent issues

Eligibility criteria:
inclusion criteria: * \>= 1 year of infertility * \>21 and \<40 years old * normal hsg * normal semen analysis (count \>= 20 million/ motility \> 50%/ kruger morph \> 14%. * absent menses * willingness to sign informed consent for study randomization * willingness to participate in 3 months of treatment. exclusion criteria: * abnormal semen analysis * abnormal hsg * medical condition that would contraindicate pregnancy, ovulation induction or general anesthesia * family history of significant genetic disease, or factor v leiden thrombophilia * inability to present for monitoring visits * inability to follow medication instruction * desire to undergo other fertility treatments before completing three months of this trial

Keywords: dhea pof pregnancy ovarian failure otherwise unexplained infertility ovarian aging
cisplatin in castration resistant prostate cancer

Conditions: Prostate Cancer

Summary: it is hypothesized that treatment with cisplatin will reverse emerging refractoriness to enzalutimide in patients with crpc by affecting ar function.


Eligibility criteria:
inclusion criteria: * histologic diagnosis of prostate cancer * age 18 yrs or older * able to provide written, informed consent * subjects who have received docetaxel for metastatic disease are eligible if absolute neutrophil count is greater than 100 and platelet count is greater than 100,000 and their bone marrow reserve is deemed to be adequate * subjects with castration resistant prostate cancer, as defined by having testosterone level of less than 50 nano gram/dl, being treated with enzalutamide with a rise in psa, confirmed with a repeat measurement within 1 to four weeks, or asymptomatic radiographic progression exclusion criteria: * subjects with estimated glomerular filtration rate of less than 50 ml/min * subjects with hearing impairment. the treating physician may decide which subjects should not receive cisplatin based on audiometry or based on clinical judgment. * subjects with grade 2 or greater neuropathy * subjects who in the opinion of the treating physician could not tolerate the standard hydration before receiving cisplatin * chemotherapy naïve subjects who in the opinion of the treating physician should receive docetaxel instead of enrolling on the trial and receive cisplatin
trial of imo-8400 in adult patients with dermatomyositis

Conditions: Dermatomyositis

Summary: the purpose of this study is to determine how safe and effective imo-8400 is in adults with dermatomyositis.

this study will evaluate the safety and efficacy of imo-8400 in adults with active dermatomyositis (dm).

Eligibility criteria:
inclusion criteria: * has definite or probable dm based on the criteria of bohan and peter * has a cutaneous dermatomyositis disease area and severity index (cdasi)-activity score ≥15 * patients with muscle weakness are eligible; however having muscle weakness is not mandatory. * study participants must have a diagnostic evaluation for cancer if the diagnosis of dm was within 2 years prior to the screening visit exclusion criteria: * has ongoing severe dysphagia (e.g., requires a feeding tube) for the 3 months prior to screening * has known hypersensitivity to any oligodeoxynucleotide * has a history of drug or alcohol abuse within one year of screening, or evidence of drug abuse by urine drug screening * has body weight \>140 kg * has a diagnosis of juvenile dm, ibm, drug-induced toxic myopathy, metabolic myopathy, dystrophy, cancer-associated dm, or connective tissue disease-associated dm (e.g., overlap syndrome) * has received one or more of following prohibited treatments within the interval noted prior to screening (visit 1): 1. rituximab within 24 weeks (note: patients who received rituximab are only eligible for inclusion if b-cell counts are confirmed to be within normal limits) 2. intravenous corticosteroids within 12 weeks 3. antimalarials (e.g., hydroxychloroquine) within 36 weeks 4. topical corticosteroids (excluding scalp) within 2 weeks * has evidence of or has required treatment for cancer (except for treated, non-invasive carcinoma of the skin or cured cervical carcinoma-in-situ) within 5 years * has interstitial lung disease requiring the use of supplemental oxygen

Keywords: dermatomyositis imo-8400 pioneer
pharmacodynamics study of imipenem in patients with ventilator associated pneumonia

Conditions: Ventilator Associated Pneumonia

Summary: imipenem is a carbapenem antibacterial agent with a broad spectrum of activity against gram-negative and gram-positive bacteria. this agent is often used as the last line of therapy for highly resistant gram negative bacilli nosocomial infections. in common with other beta-lactamase inhibitor, the main pharmacokinetic/pharmacodynamic (pk/pd) index that correlates with the therapeutic efficacy is the time that concentrations in the tissue and serum are above the mic and administration by continuous infusion is the preferred mode of administration to maximize this parameter. however, in tropical countries, the stability of carbapenem antibiotics is an important consideration when considering continuous infusion. therefore, prolonged infusion may be a useful mode of administration to maximize bactericidal activity. this study will demonstrate the stability of imipenem in clinical use at room temperature in tropical countries.


Eligibility criteria:
inclusion criteria: * patients aged \> or = 20 years * patients who have vap with gram negative bacilli infections which are sensitive to imipenem by the disk diffusion exclusion criteria: * patients who have documented hypersensitivity to imipenem or other carbapenems * patients who have an estimated creatinine clearance of \< or = 60 ml/min * patients who are in circulatory shock * patients who are pregnant

Keywords: patients with ventilator-associated pneumonia
determine impact of multiple nab tests on treatment compared to usual care of ms patients on high-dose ifn therapy

Conditions: Multiple Sclerosis

Summary: an observational study to determine the impact of multiple neutralizing antibody (nab) tests on treatment patterns compared to the usual care of ms patients receiving high-dose ifn therapy.

an observational study to determine the impact of multiple neutralizing antibody (nab) tests on treatment patterns compared to the usual care of ms patients receiving high-dose ifn therapy.

Eligibility criteria:
inclusion criteria: * willing to provide informed consent. * male or female, 18 years of age or older, with a diagnosis of ms. exclusion criteria: * has been on oral or parenteral corticosteroid therapy within the two weeks prior to the baseline visit. * has been treated with immunoglobulins (igg) or plasmapheresis within the last six months. * has any condition which the investigator or nurse feels may interfere with participation in the study or with assessments for the full duration of the study. * previously participated in this study. * has received an experimental drug in the last thirty (30) days.

Keywords: high-dose interferon neutralizing antibodies
effect of erector spinae plane block on postoperative nausea and vomiting

Conditions: Anesthesia; Pain, Postoperative; Nausea and Vomiting, Postoperative

Summary: this study will investigate the hypothesis that preoperative erector spinae plane (esp) block will reduce the incidence of postoperative nausea and vomiting (ponv) in patients undergoing elective lumbar disc herniation (ldh) surgery. ponv was defined as the presence of nausea and vomiting within 24 hours postoperatively.

the study will include patients aged 18 years and older, with (american society of anesthesiologists) asa physical status i and ii, and scheduled for single-level lumbar disc herniation surgery under general anesthesia. patient characteristics (age, gender, body mass index, etc.), apfel score, postoperative nausea and vomiting (ponv) status, intraoperative opioid use requirement, surgical duration, postoperative pain status, rescue analgesic and emetic requirement will be recorded. the primary outcome parameter will be the ponv incidence within the postoperative 24 hours. ponv severity during this period will be assessed using a likert scale from 0 to 10. ponv will be defined as vomiting, marked nausea (numerical rating scale \[nrs\] ≥4), and/or need for rescue medication. patients will be assessed for ponv at 0, 2, 4, 12, and 24 hours using the likert scale. nausea and its severity, vomiting attacks, need for intraoperative opioid use, pain and its severity, need for additional analgesics, and administration of antiemetic rescue medication will be evaluated as secondary outcome parameters.

Eligibility criteria:
inclusion criteria: * age 18 and above * asa physical status i to ii * one lumbar disc herniation surgery under general anesthesia exclusion criteria: * body mass index \>35 kg/m²) * history of drug use * nausea and vomiting before surgery * psychiatric disorders * use of antipsychotic or antiemetic drugs * severe heart disease * central nervous system diseases * vertebrobasilar artery insufficiency * cytostatic therapy * vestibular diseases * renal and/or hepatic dysfunction * pregnant patients * presence of bleeding diathesis * patients in a condition where cooperation cannot be established in the post-operative period (mental retardation etc.) * patient's refusal to accept the block procedure * allergy to local anesthetics * injection site infection

Keywords: erector spinae plane block postoperative nausea vomiting apfel score
the investigation of acute effects of action observation training on upper extremity functionality, reaction time and cognitive functions in right-handed healthy subjects

Conditions: Right-handed Healthy Adults

Summary: the aim of the study is to investigate the acute effects of action observation training on upper extremity functionality, reaction times, and cognitive functions in right-handed healthy subjects.


Eligibility criteria:
inclusion criteria: * \>18 years old * willingness exclusion criteria: * any kind of neurological or musculoskeletal problems * sight problems * pain in the upper limb * left handedness
evaluation of spirometry expert support in general practice

Conditions: Pulmonary Disease, Chronic Obstructive; Asthma; Cough; Dyspnea

Summary: more and more general practitioners (gps) use spirometry in their practices. at this time, there is sufficient reason to presume that, after a single postgraduate training program without any further support, most gps have insufficient knowledge and ability to assure valid interpretation of their spirometry tests. therefore, some kind of continuous diagnostic support with regard to spirometry interpretation by gps is advisable. the aim of the present study is to assess whether implementation of spirometry expert support (either by a computerised expert system or a working agreement between general practitioners and respiratory consultants with respect to spirometry interpretation) causes changes in diagnosing and appropriateness and efficiency of medical care in subjects with chronic respiratory morbidity managed in general practice.

more and more general practitioners (gps) use spirometry in their practices. at this time, there is sufficient reason to presume that, after a single postgraduate training program without any further support, most gps have insufficient knowledge and ability to assure valid interpretation of their spirometry tests. therefore, some kind of continuous diagnostic support with regard to spirometry interpretation by gps is advisable. the problem formulation for the study proposed is: "does implementation of spirometry expert support (either by a computerized expert system or a local working agreement between gps and respiratory consultants with respect to spirometry interpretation) cause changes in diagnosing and quality and efficiency of medical care in subjects with chronic respiratory morbidity managed in general practice?". in order to address this issue, two separate studies with different designs are proposed. study i (n=62 gps) is an 'in-depth' study of the gps' decision-making process with regard to spirometry, and the impact of a computerized expert system on this process. study ii (n=39 general practices) is a pragmatic randomised-controlled implementation study evaluating two realistic modes of spirometry expert support (i.e., a computerized expert system or a working agreement between gps and respiratory consultants).

Eligibility criteria:
inclusion criteria: * gp practices with a windows supported electronic patient journal system (pjs) in a certain postal region in the netherlands. exclusion criteria: * gp practices without a windows supported pjs * practices outside a certain postcode region

Keywords: pulmonary disease, chronic obstructive family practice spirometry decision support systems feedback
colchicine for the stability of coronary plaque in acute coronary syndrome (coloct)

Conditions: Acute Coronary Syndrome

Summary: evidence from the colcot trial has shown that anti-inflammatory effect of colchicine reduced the risk of cardiovascular events in patients with recent myocardial infarction. we hypothesized that this might be due to the improvement of the coronary plaque stability by colchicine. optical coherence tomography (oct) is the most precise method to detect plaque stability in clinical practice. thus, the purpose of this study is to evaluate the efficacy and safety of colchicine on improving the stability of coronary plaque in patients with acute coronary syndrome.

this is a single-center, randomized, double-blind, placebo-controlled clinical trial. oct coronary images analyzed at an independent imaging core laboratory (department of cardiology, second affiliated hospital of harbin medical university, harbin, china) by blinded expert readers.

Eligibility criteria:
inclusion criteria: 1. participants who understand and sign the informed consent form voluntarily. 2. age ≥ 18 years old and ≤ 80 years old, regardless of sex. 3. hospitalized patients diagnosed with acute coronary syndrome within 1 month. 4. at least one non-culprit lesion with diameter stenosis percentage of 30% to 70% by visual estimation on coronary angiography (cag) after completing any planned percutaneous revascularization. 5. the lesion shown by oct was lipid-rich plaque (lipid pool arc \> 90 °). exclusion criteria: 1. allergic to colchicine. 2. colchicine was taken within 10 days before randomization. 3. abnormal liver function (alt \> 3 times the upper limit of normal value). 4. abnormal renal function (creatinine clearance rate \< 45 ml/min). 5. thrombocytopenia (plt \< 100g/l). 6. uncontrolled infectious diseases during the screening period. 7. known immune diseases or immune-related diseases such as systemic lupus erythematosus, asthma, inflammatory bowel disease, gout, malignant tumor and so on. 8. pre-existing or plan for the administration of systemic anti-inflammatory treatments such as non-steroidal anti-inflammatory drugs, hormones, immunomodulatory and chemotherapeutic drugs. 9. history of surgery or interventional therapy within 6 months prior to the screening period. 10. a history of coronary artery bypass grafting or a plan for coronary artery bypass grafting within 1 year. 11. left main coronary disease (≥50% reduction in lumen diameter by angiographic visual estimation). 12. significant coronary calcification or tortuosity deemed to preclude oct evaluation. 13. diagnosed with mental disorders such as anxiety or depression. 14. pregnant women, lactating women or women of childbearing age who do not use effective contraceptive methods. 15. participated in other clinical trials within 3 months before the screening period. 16. do not receive standardized treatment after being diagnosed with coronary heart disease. 17. the life expectancy of the subjects is less than 1 year. 18. the researchers determined that other conditions in which the patient was not suitable to participate in the clinical trial.